All In Biotech

Drug Trial Radar · NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Mar 4, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Conditions

  • NSCLC Adenocarcinoma
  • Gastroesophageal Cancer (GC)
  • Gastric Adenocarcinoma
  • Adenocarcinoma of Esophagus
  • Squamous Cell Car. - Esophagus
  • Urothelial Carcinoma (UC)
  • Bladder Cancer
  • Mesothelioma
  • Pleural Mesothelioma
  • Peritoneal Mesothelioma
  • Non-Small Cell Lung Cancer NSCLC
  • Pancreatic Cancer
  • Biliary Tract Carcinoma

Interventions

  • IDE892Drug

    IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions.

  • IDE397Drug

    IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)Time frame: 21 days following the first dose of IDE892 (each cycle is 21 days)
  2. Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)Time frame: From first dose until 28 days after last dose (each cycle is 21 days)
  3. Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)Time frame: Approximately 2 years

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope Cancer Center-Phoenix

    Goodyear, Arizona · Recruiting

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • City of Hope Cancer Center-Duarte

    Duarte, California · Recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Johns Hopkins Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • BRCR Global-Coral Springs

    Coral Springs, Florida · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • City of Hope Cancer Center-Chicago

    Zion, Illinois · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • START Astera, LLC

    East Brunswick, New Jersey · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • START Dallas Fort Worth

    Fort Worth, Texas · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • NEXT Oncology Houston

    Houston, Texas · Recruiting

  • NEXT Oncology Dallas

    Irving, Texas · Recruiting

  • START Mountain Region, LLC

    West Valley City, Utah · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.